Conditions: Hepatitis C, Chronic
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 75
Healthy volunteers: no

Brief summary:
The main purpose of this clinical trial with BI 207127 is to see the effect of 4 week combination of BI 207127 with Peginterferon alfa (Peg-IFN) and Ribavirin (RBV) on hepatitis C virus (HCV) virus load and how safe BI 207127 is in this combination in HCV infected patients.

Detailed description:

Arms:
arm 1: BI 207127 low dose tid + SOC arm 2: BI 207127 middle dose tid + SOC arm 3: BI 207127 high dose tid +SOC arm 4: Placebo tid +SOC

Interventions: intervention 1: BI 207127 middle dose +SOC intervention 2: BI 207127 high dose+SOC intervention 3: Placebo + SOC intervention 4: BI 207127 low dose + SOC
Intervention descriptions: intervention 1: BI 207127 middle dose tid + SOC intervention 2: BI 207127 high dose tid +SOC intervention 3: Placebo tid +SOC intervention 4: BI 207127 low dose tid + SOC

Protocol document: